ENGN (enGene Therapeutics) Inventory Turnover: 0.00 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENGN enGene Therapeutics Inc ENGN
12 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Inventory Turnover?

enGene Therapeutics ENGN +1.78% 12 Inventory Turnover is 0.00 as of Apr. 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. enGene Therapeutics's Cost of Goods Sold for the three months ended in Apr. 2026 was $0.00 Mil. enGene Therapeutics's Average Total Inventories for the quarter that ended in Apr. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

enGene Therapeutics  (NAS:ENGN) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

enGene Therapeutics's Days Inventory for the three months ended in Apr. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Apr. 2026 )/Cost of Goods Sold (Q: Apr. 2026 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

enGene Therapeutics's Inventory to Revenue for the quarter that ended in Apr. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Apr. 2026 ) / Revenue (Q: Apr. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

enGene Therapeutics Inventory Turnover Related Terms

enGene Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for enGene Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Therapeutics Inventory Turnover Chart

enGene Therapeutics Annual Data
Trend Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Inventory Turnover
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

enGene Therapeutics Quarterly Data
Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ENGN
12GF Score
enGene Therapeutics Inc ENGN
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enGene Therapeutics Inventory Turnover Calculation

enGene Therapeutics's Inventory Turnover for the fiscal year that ended in Oct. 2025 is calculated as

Inventory Turnover (A: Oct. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Oct. 2025 ) / ((Total Inventories (A: Oct. 2024 ) + Total Inventories (A: Oct. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

enGene Therapeutics's Inventory Turnover for the quarter that ended in Apr. 2026 is calculated as

Inventory Turnover (Q: Apr. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Apr. 2026 ) / ((Total Inventories (Q: Jan. 2026 ) + Total Inventories (Q: Apr. 2026 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
enGene Therapeutics (ENGN) has a Inventory Turnover of 0.00 as of Apr. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on enGene Therapeutics and its competitors.
Is enGene Therapeutics' Inventory Turnover too high?
enGene Therapeutics' current Inventory Turnover is 0.00. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Inventory Turnover compare to VTVT and GUTS?
enGene Therapeutics' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current Inventory Turnover is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges S0N0:Germany
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score

Get the complete analysis for ENGN

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price